Vanta Bioscience share price
BSE: 540729Healthcare ServicesSmall Cap
Vanta Bioscience Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Oct 2017
Last close ₹20.40down ₹0.02 (0.10%)
Share price at the BSE close on 16 Oct 2026. Previous close ₹20.42.
16 Oct: open ₹20.40, high ₹20.40, low ₹20.40
52-week range of traded prices to 16 Oct 2026
₹14.71Low, 24 Mar 2026₹29.00High, 23 Oct 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹15 Cr4,396th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 133.97
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 0.69
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 0.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 1.80
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 1,500
Results
Standalone, as consolidated accounts are on record for only 8 of the last ten years; ₹ crore.Vanta Bioscience half-yearly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- −7.5%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- –
Half year to Mar 2026, against the half year before
- RevenueRevenue. The pill is the change in revenue against the half year before: this period's figure divided by that one's, less one, in per cent.
- ₹1.51 Crup 401.86%
- Net profitNet profit. Under it, net profit in the half year before. A change in per cent is not worked out where either period is a loss or nothing. Net profit in the glossary
- ₹1.93 CrHalf year to Sep 2025: −₹1.81 Cr
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 127.6%
Revenue by half year
Peak revenue ₹5.23 Cr, half year to Sep 2023; lowest ₹0.30 Cr, half year to Sep 2025
Net profit by half year, a loss in red
- Net profit
- Loss
Back to profit in the half year to Mar 2026, ₹1.93 CrA loss in 5 of the 7 half years shown
| ₹ crore | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | 3.47 | 5.23 | 3.33 | 0.80 | 0.33 | 0.30 | 1.51 |
| Net profit | −2.73 | 0.12 | −0.07 | −1.29 | −1.43 | −1.81 | 1.93 |
| Net margin | −78.7% | 2.4% | −2.2% | −161.5% | −438.3% | −600.8% | 127.6% |
Standalone. The last eight half years, but for those filed as quarters, which are below. The latest is shaded.
| ₹ crore | Sep 2022 |
|---|---|
| Revenue | 1.71 |
| Net profit | −1.51 |
| Net margin | −88.4% |
Standalone. The quarters the company also filed in the same span.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹1.82 Crup 61.11%
- Net profitNet profit. Under it, net profit in the year before. A change in per cent is not worked out where either period is a loss or nothing.
- ₹0.12 CrYear to Mar 2025: −₹2.78 Cr
- Net margin
- 6.6%
Revenue by year
Peak revenue ₹14 Cr, year to Mar 2020; lowest ₹1.13 Cr, year to Mar 2025
Net profit by year, a loss in red
- Net profit
- Loss
Back to profit in the year to Mar 2026, ₹0.12 CrA loss in 2 of the 9 years shown
| ₹ crore | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.0 | 12.4 | 14.1 | 10.0 | 9.3 | 5.2 | 8.6 | 1.1 | 1.8 |
| Net profit | 0.0 | 0.7 | 1.0 | 0.5 | 0.1 | −4.2 | 0.1 | −2.8 | 0.1 |
| Net margin | 0.7% | 5.6% | 6.9% | 4.7% | 0.8% | −81.9% | 0.6% | −246.5% | 6.6% |
Standalone. Years to March. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, Pre-clinical contract research organisation, which carries all its revenue.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −31.5% | – | – | 0.0% |
| 3 years | −35.9% | – | – | 0.0% |
| 5 years | −37.8% | −25.6% | −16.4% | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth and the change in P/E are left empty where earnings per share at either end of the window was a loss or is not on record. Earnings growth over 1 year is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count.
Vanta Bioscience competitors and peers
Healthcare Research, Analytics & Technology, 11 listed companies, priced on 28 Oct 2026. The table lists the 8 companies closest to Vanta Bioscience in market cap. Vanta Bioscience's own figures are from its last trade, on 16 Oct 2026. 1 company in the table last traded before then: its row is priced on its last trade.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Suven Life SciencesSUVEN | 7,574 | – | – | +17.3% | – | −100.5% | −63.0% | 0.00% |
 Vimta LabsVIMTALABS | 2,295 | 28.81 | 5.02 | +15.2% | – | 19.1% | 21.4% | 0.39% |
 BilcareBI | 192 | – | 0.97 | −0.9% | – | – | 5.4% | 0.00% |
 Novelix PharmaceuticalsNOVELIX | 175 | 48.19 | – | +179.9% | – | 11.3% | 8.7% | 0.00% |
 Jeevan Scientific TechnologyJSTL | 164 | – | 2.28 | +66.1% | – | – | 8.8% | 0.00% |
 TAKETAKE | 156 | 12.16 | 5.03 | – | −68.2% | 49.8% | −5.6% | 0.00% |
 GlobalSpace Technologies540654 | 82 | – | 1.44 | +37.2% | – | – | 7.5% | 0.00% |
 Adeshwar MeditexADESHWAR | 23 | 18.03 | 0.60 | – | – | 3.4% | – | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Vanta Bioscience announcements
Sep 2026
5 Sep · Board meeting
May 2026
30 May · Results
26 May · Board meeting
Meeting on 30 May 2026: audited results
Vanta Bioscience share price by year
Each calendar year to 2025.Vanta Bioscience share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 23.50 | −47.1% | 42.85 | 18.72 |
| 2024 | 44.44 | −17.0% | 101.62 | 38.29 |
| 2023 | 53.55 | −15.9% | 76.70 | 39.71 |
| 2022 | 63.65 | −49.8% | 181.00 | 60.80 |
| 2021 | 126.75 | −2.5% | 190.15 | 105.00 |
| 2020 | 130.00 | +17.3% | 190.50 | 80.00 |
| 2019 | 110.80 | +30.9% | 195.00 | 83.00 |
| 2018 | 84.65 | +24.9% | 111.50 | 46.00 |
| 2017 | 67.75 | – | 72.00 | 44.10 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2017 is from its first session, 6 Oct 2017.
Recent sessions
The 9 trading days to 15 Oct 2026, as traded on BSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 15 Oct 2026 | 20.42 | 20.42 | 20.42 | 20.42 | 20.42 | 750 |
| 6 Oct 2026 | 20.42 | 20.42 | 20.42 | 20.42 | 20.42 | 2,250 |
| 5 Oct 2026 | 20.50 | 20.50 | 20.42 | 20.42 | 20.43 | 5,250 |
| 1 Oct 2026 | 21.50 | 21.50 | 21.49 | 21.49 | 21.49 | 2,250 |
| 30 Sep 2026 | 22.22 | 22.62 | 22.22 | 22.62 | 22.42 | 3,000 |
| 29 Sep 2026 | 21.55 | 21.55 | 21.55 | 21.55 | 21.55 | 750 |
| 28 Sep 2026 | 18.59 | 20.53 | 18.59 | 20.53 | 19.56 | 1,500 |
| 24 Sep 2026 | 21.60 | 21.60 | 19.56 | 19.56 | 20.24 | 2,250 |
| 10 Sep 2026 | 18.62 | 20.58 | 18.62 | 20.58 | 18.90 | 5,250 |
Prices in ₹ per share as traded, not adjusted.
Company details
- BSE code
- 540729
- ISIN
- INE695X01011
- Industry
- Healthcare Services
- Website
- www.vantabio.com
- CIN
- L74999TG2016PLC109280
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 2016
- Registered office
- NO.02/G/308/G, NO.3/FF/SF/1-20-248, Umajay Complex, Rasoolpura, Secunderabad, Hyderabad 500003, Telangana
- Share registrar
- Bigshare Services Pvt. Ltd
- Keeps the register of shareholders and handles transfers and dividend payments